8-K: GoHealth Secures Superpriority Debt, Issues Equity to Lenders

Sentiment:

Debt Restructuring and Capital Raise 7 August 2025 7:08 AM

GoHealth, Inc. has completed a significant financial restructuring, securing new superpriority debt and issuing a substantial equity stake to lenders to enhance liquidity and financial flexibility.

Delay expectedDelayed-draw term loans of $40.0 million are available in tranches, with specific funding limits of $15.0 million by November 1, 2025, and $30.0 million by December 1, 2025, before the full amount is available.Amortization payments on the Existing Term Loans are waived until December 31, 2026.

Capital raiseSecured a new $115.0 million Superpriority Senior Secured Credit Agreement, including $80.0 million in new-money term loans and $35.0 million from a cashless roll-up of existing revolving loans.Issued 4,766,219 shares of Class A common stock to lenders, representing 19.99% of the total issued and outstanding common stock prior to the transaction.Created a debt basket capacity of up to $250.0 million for potential transformative transactions.

Worse than expectedThe company reported a net loss of $(115.989) million for Q2 2025, a significant increase from the net loss of $(59.314) million in Q2 2024.A substantial intangible asset impairment charge of $53.0 million was recorded, indicating a write-down of asset values.The need for a new superpriority credit facility with high interest rates and a MOIC, along with the issuance of a significant equity stake (19.99%) to lenders, suggests a distressed financing scenario.The waiver of near-term principal payments and the option for PIK interest on existing debt further highlight financial strain and a need for immediate cash preservation.

Summary

GoHealth, Inc. (GOCO) and its subsidiaries, including Norvax, LLC (the Borrower) and Blizzard Midco, LLC (Holdings), entered into a new Superpriority Senior Secured Credit Agreement (Priming Credit Agreement) on August 6, 2025.
The Priming Facility totals $115.0 million, comprising $80.0 million in new-money term loans and $35.0 million from a cashless conversion of existing Class A revolving loans at par.
Of the new-money term loans, $40.0 million was funded on the closing date, with an additional $40.0 million available as delayed-draw term loans.
Delayed-draw term loans will be available from October 1, 2025, with funding limits of $15.0 million prior to November 1, 2025, and $30.0 million prior to December 1, 2025, with the full amount available thereafter.
The Priming Term Loans mature on August 5, 2029.
New-money term loans bear interest at Term SOFR plus 5.50% per annum (with a 3.00% SOFR floor) or Alternate Base Rate plus 4.50% (with a 4.00% ABR floor).
New-money term loans are subject to a 2.00x Multiple-on-Invested-Capital (MOIC), stepping down to 1.75x for repayments between January 1, 2026, and April 1, 2027, and to 1.50x for repayments prior to January 1, 2026.
The company amended its Existing Credit Agreement (Amendment No. 14), terminating all Class A-1 and Class A revolving commitments, and extending the maturity of remaining Class A revolving loans to August 5, 2029.
The amendment permits GoHealth to pay a portion of interest on outstanding Existing Term Loans and Class A revolving loans in kind (PIK), with interest accruing at Adjusted Term SOFR plus 8.00% per annum, of which at least Adjusted Term SOFR plus 4.50% per annum must be paid in cash.
Amortization of the Existing Term Loans is waived until December 31, 2026.
The amendment removes the total cash leverage covenant, asset coverage covenant, and budget variance covenant from the Existing Credit Agreement.
An event of default under the Priming Credit Agreement will not trigger an event of default under the Amended Credit Agreement unless the Priming Term Loan Obligations have been accelerated.
GoHealth issued 4,766,219 shares of Class A common stock to lenders (Subscribers), representing 19.99% of the total issued and outstanding Class A and Class B common stock prior to the transaction.
The company reported a net loss of $(115.989) million for the three months ended June 30, 2025, compared to a net loss of $(59.314) million for the same period in 2024.
Adjusted EBITDA for the three months ended June 30, 2025, was $(11.295) million, compared to $(12.308) million for the same period in 2024.
An intangible asset impairment charge of $53.0 million was recorded for the three and six months ended June 30, 2025.
Sales per Submission decreased to $657 for Q2 2025 from $690 for Q2 2024, and Direct Operating Cost per Submission decreased to $613 from $641 for the same periods.

Sentiment

Score: 2

Explanation: The filing indicates severe financial distress, characterized by a large net loss, significant intangible asset impairment, and the necessity of a distressed financing package. The new superpriority debt, high interest rates, MOIC, and substantial equity dilution for existing shareholders point to a precarious financial position, despite management's positive framing of 'enhanced financial flexibility'.

Positives

Secured $80.0 million in new-money term loans, providing immediate and expandable capital to support working capital and strategic flexibility.
Extended the maturity date of remaining Class A revolving loans to August 5, 2029, providing longer-term liquidity.
Waiver of near-term principal payments on Existing Term Loans until December 31, 2026, easing immediate debt service burden.
Ability to pay a portion of interest on existing and new loans in kind (PIK), preserving cash.
Established a debt basket capacity of up to $250.0 million under the new superpriority term loan facility and amended credit agreement for potential transformative transactions.
Appointment of three new directors and establishment of a Transformation Committee to align governance with forward-looking strategic direction and assess strategic alternatives.

Negatives

Incurred new superpriority debt, which ranks senior to existing debt, potentially reducing recovery for existing lenders in a default scenario.
New-money term loans carry a high Multiple-on-Invested-Capital (MOIC) of up to 2.00x, indicating a high cost of capital.
Issued 4,766,219 shares of Class A common stock to lenders, representing 19.99% dilution to pre-transaction equity holders.
Reported a significant net loss of $(115.989) million for Q2 2025, a substantial increase from $(59.314) million in Q2 2024.
Recorded a $53.0 million intangible asset impairment charge, indicating a reduction in asset value.
Sales per Submission decreased by 4.8% in Q2 2025 compared to Q2 2024, suggesting a decline in per-submission revenue efficiency.
The removal of the total cash leverage covenant, asset coverage covenant, and budget variance covenant from the Existing Credit Agreement suggests prior difficulty in meeting these metrics, despite new liquidity covenants in the Priming Credit Agreement.
The need for such a distressed financing package indicates severe financial challenges and liquidity constraints.

Risks

Inability to realize expected benefits from strategic capital and governance actions.
Challenges in executing strategic alternatives or objectives, including transformative transactions.
High level of indebtedness and associated debt service obligations.
Maintaining minimum liquidity covenants, which start at $5.0 million and increase to $30.0 million by September 27, 2026.
Potential for further intangible asset impairment charges.
Impact of regulatory changes on the business.
Risks associated with the integration of e-TeleQuote Insurance, Inc. operations, technologies, and employees.
Restrictions on future liability management transactions without specific lender consent.
Restrictions on future financings, potentially limiting access to capital.

Future Outlook

Management expects the new credit facility and access to immediate and expandable capital to enable the company to maintain compliance with debt covenants and fund operations for the next 12 months and beyond. The company plans to continue serving the Medicare market, pursue disciplined growth, and assess transformative opportunities, positioning itself to act decisively and responsibly in support of its strategic objectives.

Management Comments

Vijay Kotte, CEO: "Our strategic capital and governance actions reflect our commitment to long-term stockholder value creation and our belief that GoHealth is structurally and strategically positioned to lead in a consolidating industry. With the new credit facility and the access to immediate and expandable capital it provides, we believe we are operating from a position of strength as we continue to serve the Medicare market, pursue disciplined growth and assess transformative opportunities."
Brendan Shanahan, CFO: "The amendment to our existing credit agreement provides important financial flexibility. Through this strategic financing arrangement, we have the ability to evaluate and pursue strategic transactions. We believe these enhancements position us to act decisively and responsibly in support of our strategic objectives."

Industry Context

GoHealth operates as a health insurance marketplace and Medicare-focused digital health company. The CEO's comments indicate a belief that the company is positioned to lead in a 'consolidating industry,' suggesting ongoing M&A activity or market share shifts among competitors in the health insurance and Medicare brokerage space.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Class I Director	NA	Timothy R. Pohl	2025-08-06	Appointment as a condition to lenders' entry into new credit agreements.
Class II Director	NA	Alan J. Carr	2025-08-06	Appointment as a condition to lenders' entry into new credit agreements.
Class III Director	NA	William L. Transier	2025-08-06	Appointment as a condition to lenders' entry into new credit agreements.
Director	Karoline Hilu	NA	2025-08-06	Resignation as a condition to lenders' entry into new credit agreements.
Director	Alexander E. Timm	NA	2025-08-06	Resignation as a condition to lenders' entry into new credit agreements.
Director	Alan Wheatley	NA	2025-08-06	Resignation as a condition to lenders' entry into new credit agreements.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Committee Establishment	Established a new 'Transformation Committee' of the Board of Directors, consisting of Alan J. Carr, Timothy R. Pohl, William L. Transier, and Jeremy W. Gelber. This committee has exclusive power to review, formulate, negotiate, and recommend strategic alternatives (refinancings, securitizations, M&A, restructurings) and will work with the Compensation Committee on employee incentive plans.	2025-08-06	Centralizes strategic decision-making and oversight of critical financial and operational initiatives, potentially indicating a need for rapid and decisive action.
Committee Appointments	Alan J. Carr and William L. Transier were appointed to the Audit Committee. William L. Transier was appointed as a member and Chair of the Nominating and Corporate Governance Committee.	2025-08-06	Integrates new directors into key oversight functions, potentially bringing fresh perspectives or lender-aligned interests to financial and governance matters.
Director Term Limits/Renomination	Appointed Directors are expected to serve for no longer than four years from the Closing Date and will tender their resignation on the fourth anniversary. The Board will renominate Appointed Directors upon term expiration prior to the fourth anniversary.	2025-08-06	Establishes a defined tenure for the newly appointed directors, potentially providing a clear transition plan or a mechanism for lender influence over a specific period.
Board Composition Restrictions	Prior to the fourth anniversary of the Effective Date, the Board is restricted from increasing/decreasing the number of directors, removing/replacing Appointed Directors, or filling Appointed Director vacancies without the prior written consent of the Required Term Lenders.	2025-08-06	Grants significant control to the Required Term Lenders over the composition and stability of the Board, reflecting increased lender influence due to the distressed financing.
Observer Rights	The Required New Money Term Lenders and Required Rolled Term Lenders have the right to designate non-voting Parent Board Observers to attend all Board and committee meetings.	2025-08-06	Provides lenders with direct oversight and access to strategic discussions and financial performance, enhancing their ability to monitor the company's operations and protect their investment.

Related Party Transactions

Issued 4,766,219 shares of Class A common stock to lenders (Subscribers) as part of the financing, making them significant equity holders.
Permitted transactions with affiliates, including loans and advances to officers/directors/employees for business purposes or equity purchases, and payments to Parent Entity for operating expenses, indemnification, and certain fees, subject to specific limitations and conditions (e.g., $1.0 million limit on certain fees during a 'Suspension Period').

Stakeholder Impact

Shareholders: Experience significant dilution (19.99% of common stock issued to lenders) and face increased risk due to the company's distressed financial state and the senior ranking of new debt. Future equity value is highly uncertain.
New Money Term Lenders: Benefit from a senior secured superpriority position, high interest rates, and a substantial MOIC, along with significant governance rights (board appointments, observer rights, consent rights over key actions).
Existing Lenders: Their debt is now subordinated to the new superpriority facility. While they receive some concessions (PIK interest, amortization waiver), their recovery prospects in a liquidation scenario are diminished.
Management/Employees: New board members and the Transformation Committee will influence strategic direction and potentially compensation structures (e.g., new employee incentive plans).
Customers: No direct impact is mentioned, but the company's financial stability and strategic focus on the Medicare market could indirectly affect service quality and product offerings.

Next Steps

Draw down delayed-draw term loans, with specific amounts available by November 1, 2025 ($15.0 million) and December 1, 2025 ($30.0 million).
Continue to serve the Medicare market and pursue disciplined growth.
Assess and potentially pursue transformative opportunities, leveraging the new debt basket capacity.
The Board's Transformation Committee will review and formulate strategic alternatives, including refinancings, securitizations, mergers, acquisitions, and restructurings.
The Transformation Committee will also work with the Compensation Committee to review and recommend future employee incentive plans.

Key Dates

Date	Description
2025-08-06	Closing Date for the Superpriority Senior Secured Credit Agreement and Amendment No. 14 to the Existing Credit Agreement.
2025-08-07	Press release issued announcing the transactions and Q2 2025 financial results; conference call held.
2025-10-01	Delayed-draw term loans become available to the Borrower.
2025-10-05	Commencement of minimum liquidity covenant of $5.0 million at the end of each calendar week.
2025-11-01	Aggregate principal amount of delayed-draw term loans funded not to exceed $15.0 million prior to this date.
2025-12-01	Aggregate principal amount of delayed-draw term loans funded not to exceed $30.0 million prior to this date.
2025-12-31	Fiscal year end for which audited consolidated financial statements will be delivered; Existing Term Loan amortization waived until this date.
2026-01-01	MOIC for Priming New Money Term Loans steps down to 1.75x for repayments prior to April 1, 2027, and to 1.50x for repayments prior to this date.
2026-03-29	Minimum liquidity covenant increases to $15.0 million at the end of each calendar week.
2026-06-28	Minimum liquidity covenant increases to $20.0 million at the end of each calendar week.
2026-09-27	Minimum liquidity covenant increases to $30.0 million at the end of each calendar week and thereafter.
2029-08-05	Maturity date for Priming Term Loans and extended Class A revolving loans.

Recommendation

strong sell

The company is undergoing a distressed financing, characterized by the issuance of superpriority debt with high interest rates and a significant MOIC, substantial equity dilution for existing shareholders (19.99% issued to lenders), and the need for waivers on existing debt amortization. The financial results show a large intangible asset impairment charge and continued net losses, indicating severe operational and financial challenges. The new debt structure subordinates existing lenders, and the new covenants, while providing some flexibility, highlight ongoing liquidity concerns. These actions suggest a company in a precarious financial position, making it a high-risk investment with significant downside potential for current equity holders.

Keywords

Debt Restructuring, Capital Raise, Superpriority Debt, Term Loans, Equity Issuance, Financial Flexibility, Corporate Governance, Medicare Market, Health Insurance, Financial Results, Liquidity, Dilution, Impairment Charge

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.